750P PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
| Autor: | Slomovitz, B.M., Raaschou-Jensen, N., Coleman, R.L., Gilbert, L., Powell, M.A., Cibula, D., Ghamande, S., Zavallone, L., Mendivil, A.A., Ataseven, B., Black, D., Wymenga, M., Billingsley, C., Willmott, L.J., McCourt, C., Podzielinski, I., Doehring, O., Garside, J., Herzog, T.J., Mirza, M.R. |
|---|---|
| Zdroj: | In Annals of Oncology October 2023 34 Supplement 2:S514-S515 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|